InvestorWire NewsRoom


New Pharmaceutical Subsidiary Geared to Aid Odyssey Health, Inc. (ODYY) Development of Novel Solutions for Brain Related Medical Treatments
November 7, 2022

New Pharmaceutical Subsidiary Geared to Aid Odyssey Health, Inc. (ODYY) Development of Novel Solutions for Brain Related Medical Treatments

  • Odyssey Health Inc. is a medical product developer with a mission of filling unmet needs when it comes to acute emergencies involving patients’ central nervous systems
  • The company recently announced the formation of a wholly owned subsidiary to help Odyssey develop its products as they move through the regulatory process
  • Odyssey’s solutions include a breath-powered intranasal delivery mechanism and synthetic neurosteroids designed to provide rapid-response treatment for patients with concussions and a highly fatal pediatric neurological disease
  • Odyssey Health also is developing solutions for heart disease detection, obstructed-airway choking and nerve agent exposure
  • The concussion therapeutic solution recently completed Phase I testing successfully and the company is preparing for Phase II efficacy testing in cooperation with military service personnel

Medical technology solutions innovator Odyssey Health (OTC: ODYY) is moving up a rung on the ladder to product success with the formation of a wholly owned pharmaceutical subsidiary focused on developing drugs to treat neurological disorders.

Odyssey has been developing and testing drug candidates to combat conditions with unmet needs, with primary area of interest being the development of drug and device combination products that will help people afflicted by central nervous system maladies. This area includes brain concussions, especially affecting military and sports personnel, in addition to a neurological disease with a high mortality rate among pediatric patients, and potentially deadly exposure to nerve gas agents.

In September, Odyssey reported completion of its Phase I clinical trial for its concussion drug candidate, PRV-002. The safety trial’s Single Ascending Dosing (“SAD”) and Multiple Ascending Dosing (“MAD”) cohorts all found the drug to be well tolerated, and Odyssey is now communicating the trial’s findings to the U.S. Food and Drug Administration (“FDA”) while beginning preparations for a Phase II trial that will seek to provide greater evidence of the drug’s effectiveness, according to a company news release (

The new subsidiary, Odyssey Neuropharma, Inc., will help advance Odyssey’s development of neurosteroids such as PRV-002 and PRV-001, which is being designed to combat the neuro-degenerative Niemann-Pick type C disease and has been shown to improve neuromotor function and reduce brain inflammation in pre-clinical studies, according to the company’s most recent news release (

Both drugs are fully synthetic and are administered via a breath-powered intranasal delivery device subject to a provisional patent application.

The Organophosphate Nerve Agent antidote similarly involves intranasal delivery of powdered oximes (a class of nitrogen-containing organic compounds) to combat the consequences of exposure to chemical weapons.

Current use of oximes as an antidote involves multiple injections but Odyssey’s attempt to develop an intranasal product offers the hope of a painless means of delivery that is fast-acting and targeted to the central nervous system.

“Odyssey’s lightweight drug device combination can be carried in the pocket of civilians around the world at risk (of nerve agent exposure) as a means of biodefense,” the company’s news release states.

Odyssey has also produced other products for potential commercial marketability, such as a device to remove a throat obstruction in a choking person and new technology for the early detection for heart disease. Each product furthers the company’s mission to develop products that fill needs for life-saving solutions to acute brain, cardiovascular and respiratory emergencies.

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at 

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Recent Articles

Release Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).